Qi Su Selected Research

diallyl disulfide (diallyl disulphide)

2/2021	Corrigendum to "Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22" [Canc. Lett. 340 (1) (Oct 28, 2013) 72-81].
1/2020	Diallyl disulfide induces downregulation and inactivation of cofilin 1 differentiation via the Rac1/ROCK1/LIMK1 pathway in leukemia cells.
1/2019	Diallyl disulfide inhibits colon cancer metastasis by suppressing Rac1-mediated epithelial-mesenchymal transition.
6/2018	[Downregulation of MCL-1 by Diallyl Disulfide Induces G2/M Arrest in Human Leukemia K562 Cells and Its Mechanism].
6/2018	Diallyl disulfide inhibits TGF‑β1‑induced upregulation of Rac1 and β‑catenin in epithelial‑mesenchymal transition and tumor growth of gastric cancer.
2/2017	Identification of potential targets for differentiation in human leukemia cells induced by diallyl disulfide.
1/2017	Downregulation of LIMK1-ADF/cofilin by DADS inhibits the migration and invasion of colon cancer.
11/2016	Subcellular localization of DJ-1 in human HL-60 leukemia cells in response to diallyl disulfide treatment.
9/2016	Involvement of calreticulin in cell proliferation, invasion and differentiation in diallyl disulfide-treated HL-60 cells.
3/2016	Diallyl disulfide suppresses epithelial-mesenchymal transition, invasion and proliferation by downregulation of LIMK1 in gastric cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qi Su Research Topics

Disease

51	Neoplasms (Cancer) 10/2022 - 08/2005
16	Stomach Neoplasms (Stomach Cancer) 02/2021 - 02/2004
13	Infections 01/2021 - 04/2011
12	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 03/2008
10	Leukemia 01/2022 - 04/2007
9	Hepatocellular Carcinoma (Hepatoma) 08/2022 - 01/2014
9	Colonic Neoplasms (Colon Cancer) 12/2021 - 08/2007
9	Neoplasm Metastasis (Metastasis) 04/2021 - 04/2004
8	Carcinogenesis 01/2021 - 04/2004
7	Breast Neoplasms (Breast Cancer) 02/2022 - 01/2013
7	Carcinoma (Carcinomatosis) 01/2022 - 04/2005
5	Mitochondrial Diseases (Mitochondrial Disease) 07/2022 - 08/2020
4	Hypoxia (Hypoxemia) 02/2022 - 12/2019
4	Inflammation (Inflammations) 11/2021 - 12/2016
3	Coinfection 01/2021 - 06/2018
2	Obesity 07/2022 - 01/2021
2	COVID-19 05/2022 - 02/2021
2	Malaria 01/2022 - 01/2017
2	Melanoma (Melanoma, Malignant) 12/2021 - 06/2021
2	Lung Neoplasms (Lung Cancer) 01/2021 - 12/2020
2	Constipation 05/2020 - 02/2018
2	Newcastle Disease 05/2019 - 08/2018
2	Hepatitis 08/2018 - 05/2018
2	Sepsis (Septicemia) 01/2017 - 11/2016
2	Shock 01/2017 - 10/2007
2	Lymphatic Metastasis 04/2016 - 04/2005
2	Prostatic Neoplasms (Prostate Cancer) 05/2010 - 09/2008
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 08/2022
1	Fever (Fevers) 05/2022
1	Toxoplasmosis 01/2022

Drug/Important Bio-Agent (IBA)

27	diallyl disulfide (diallyl disulphide)IBA 02/2021 - 02/2004
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2004
8	Peptides (Polypeptides)IBA 10/2022 - 10/2007
8	VaccinesIBA 01/2022 - 08/2018
7	sanguinarineIBA 11/2021 - 12/2019
7	CateninsIBA 01/2021 - 04/2016
6	AntigensIBA 01/2022 - 10/2007
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2007
4	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2013
4	RNA (Ribonucleic Acid)IBA 11/2021 - 03/2013
4	Cadherins (E-Cadherin)IBA 04/2021 - 03/2016
4	Attenuated VaccinesIBA 05/2019 - 05/2018
4	VimentinIBA 01/2019 - 03/2016
3	HydrogelsIBA 10/2022 - 01/2020
3	Urea (Carbamide)FDA LinkGeneric 02/2022 - 12/2020
3	NanovaccinesIBA 01/2022 - 01/2020
3	EpitopesIBA 01/2022 - 06/2021
3	AlkaloidsIBA 04/2021 - 10/2020
3	Biological ProductsIBA 01/2021 - 04/2007
3	Monoclonal AntibodiesIBA 01/2021 - 09/2008
3	Pharmaceutical PreparationsIBA 10/2020 - 05/2012
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 06/2018 - 08/2005
3	p38 Mitogen-Activated Protein KinasesIBA 06/2008 - 02/2004
2	InflammasomesIBA 08/2022 - 01/2017
2	MagnesiumIBA 05/2022 - 12/2013
2	diphenyl (biphenyl)IBA 02/2022 - 12/2020
2	Estrogen ReceptorsIBA 02/2022 - 04/2021
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2022 - 11/2021
2	PolymersIBA 01/2022 - 01/2020
2	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 11/2014
2	Therapeutic UsesIBA 01/2022 - 01/2013
2	Liposomes (Liposome)IBA 12/2021 - 06/2021
2	Protein Subunit VaccinesIBA 11/2021 - 10/2021
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2021 - 01/2020
2	Hematoxylin (Haematoxylon)IBA 04/2021 - 01/2020
2	Eosine Yellowish-(YS) (Eosin)IBA 04/2021 - 01/2020
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2021 - 06/2018
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2016
2	Serine (L-Serine)FDA Link 01/2021 - 01/2020
2	EnzymesIBA 01/2021 - 02/2015
2	Hormones (Hormone)IBA 05/2020 - 05/2010
2	Indicators and Reagents (Reagents)IBA 01/2020 - 10/2010
2	Actin Depolymerizing Factors (Cofilins)IBA 01/2020 - 01/2017
2	Carbon MonoxideIBA 12/2019 - 06/2014
2	AntibodiesIBA 05/2019 - 08/2018
2	LipopolysaccharidesIBA 01/2019 - 11/2016
2	Virulence Factors (Pathogenicity Factors)IBA 01/2017 - 11/2016
2	integrin-linked kinaseIBA 04/2014 - 04/2013
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2014 - 04/2013
2	diallyl trisulfideIBA 07/2013 - 10/2006
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2010 - 09/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2022
1	shuanghuaIBA 08/2022
1	LipidsIBA 07/2022
1	ElectrolytesIBA 05/2022
1	Phosphorus (Red Phosphorus)IBA 05/2022
1	SodiumIBA 05/2022
1	CalciumIBA 05/2022
1	Potassium Chloride FDA LinkGeneric 05/2022
1	PotassiumIBA 05/2022
1	TAD1822-7IBA 02/2022
1	taspineIBA 02/2022
1	AlbuminsIBA 01/2022
1	manganese oxide (hausmannite)IBA 01/2022
1	Thymidine PhosphorylaseIBA 01/2022

Therapy/Procedure

14	Therapeutics 02/2022 - 10/2007
6	Immunotherapy 01/2022 - 01/2020
2	Radiotherapy 10/2022 - 04/2021
2	Photothermal Therapy 01/2022 - 01/2021
2	Lasers (Laser) 01/2022 - 01/2021